Globeimmune Inc (GBIM)

$0.00 0.00 (N/A)
Market Cap 0.00
Revenue (ttm) 6.46M
Net Income (ttm) -2.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -42.88%
Debt to Equity Ratio 0.00
Volume 4,200
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 0.00
Stochastic %K 50%
Beta -312.29
Analysts Strong Buy
Price Target N/A

Company Profile

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platforms. The company's product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-620...

Industry: Biotechnology
Sector: Healthcare
Phone: 303 625 2700
Fax: 303 625 2710
Address:
1450 Infinite Drive, Louisville, United States
DotKnight
DotKnight Mar. 20 at 10:23 PM
$GBIM cannot help wandering what's the stock price of gbim if $IBRX become a trillion dollars company. 🤔 even multi trillion dollars 💸
3 · Reply
LucasRMcCain
LucasRMcCain Feb. 24 at 4:21 PM
$GBIM Just checking in here again with recent run-up in IBRX stock price. Those 163,800 shares we hold have become a lot more valuable over the past week. I continue to dream of the day they just convert out GBIM shares into IBRX shares....
1 · Reply
TheBestCard
TheBestCard Feb. 19 at 2:00 AM
$GBIM Outcomes for GBIM Shareholders Full Acquisition by ImmunityBio (IBRX) GBIM could be fully absorbed Shareholders may receive IBRX shares OR receive cash based on negotiated valuation OR receive minimal value if valuation is low Stock Exchange / Share Conversion GBIM shares converted into IBRX shares at a set ratio Cash Buyout ImmunityBio purchases remaining minority shares Could be at a premium, fair value, or low valuation Remain a Controlled Subsidiary (Status Quo) GBIM stays under ImmunityBio control Share value remains speculative/illiquid Asset Transfer / Internal Restructuring Patents/IP moved within corporate structure Limited or no direct benefit to minority shareholders Reverse Merger or Strategic Transaction GBIM used as a vehicle for another asset or deal highly speculative Dissolution / Wind-Down If dissolved, shareholders are last in priority Unexpected Value Unlock IP monetization or strategic shift increases value No current public indication of this
1 · Reply
m1965
m1965 Feb. 13 at 6:13 PM
$GBIM That sucks !! Someone sold 190 shares and dropped the price to .000099
0 · Reply
m1965
m1965 Feb. 12 at 2:58 PM
$GBIM Someone sold 3k shares this morning. One day maybe we’ll all be selling at more than $.0001
1 · Reply
dee64
dee64 Feb. 10 at 5:25 AM
$GBIM Wish I could sell $GBIM as a tax write-off.
2 · Reply
Biofrog
Biofrog Feb. 2 at 1:27 AM
$IBRX $GBIM Sorry but not correct. The 2024 annual report says that IBRX discontinued research on the Tarmogen platform due to poor trial outcomes. But GBIM's other platform is Neoepitopes. Protein constructs created using yeast which IBRX is working on. The hope is that they could be part of/ inside of the hAd5 adenoviris for Covid, Lynch, but we don't know. If they are not than IBRX will maybe cancel GBIM but they have been maintaining a large plant in Colorado for 4 years where GBIM is at.
4 · Reply
Groov
Groov Feb. 2 at 1:08 AM
$GBIM $IBRX still holding 5000 GBIM Shares @ $2.53
1 · Reply
oceanviewhi
oceanviewhi Feb. 2 at 1:02 AM
$IBRX the relationship between GlobeImmune ($GBIM) and ImmunityBio ($IBRX) ImmunityBio (via NantCell) is the majority shareholder of GlobeImmune. Dr. Pat acquired a massive stake in 2017 to secure the Tarmogen® platform, which uses heat-inactivated yeast (S. cerevisiae) to stimulate T-cell immunity. The Tarmogen technology is now a key pillar of the "BioShield" vaccine strategy. Unlike traditional vaccines that rely on antibodies, Tarmogens activate cellular immunity, which is essential for killing tumors and clearing chronic viral infections like HIV. This is the "crown jewel" of the GlobeImmune portfolio. It targets the KRAS mutation, which is present in 90% of pancreatic cancers and 30-50% of colorectal and lung cancers. In 2026, this is being integrated into "basket trials" alongside Anktiva to see if Anktiva can amplify the T-cell response generated by GI-4000.
0 · Reply
Biofrog
Biofrog Jan. 31 at 9:48 PM
$GBIM $IBRX Hello my fellow GBIM'ers. Someone on IBRX is questioning our relationship with IBRX. Go to westjitter at 3:30 if you want for fun and my replies.
0 · Reply
Latest News on GBIM
No data available.
DotKnight
DotKnight Mar. 20 at 10:23 PM
$GBIM cannot help wandering what's the stock price of gbim if $IBRX become a trillion dollars company. 🤔 even multi trillion dollars 💸
3 · Reply
LucasRMcCain
LucasRMcCain Feb. 24 at 4:21 PM
$GBIM Just checking in here again with recent run-up in IBRX stock price. Those 163,800 shares we hold have become a lot more valuable over the past week. I continue to dream of the day they just convert out GBIM shares into IBRX shares....
1 · Reply
TheBestCard
TheBestCard Feb. 19 at 2:00 AM
$GBIM Outcomes for GBIM Shareholders Full Acquisition by ImmunityBio (IBRX) GBIM could be fully absorbed Shareholders may receive IBRX shares OR receive cash based on negotiated valuation OR receive minimal value if valuation is low Stock Exchange / Share Conversion GBIM shares converted into IBRX shares at a set ratio Cash Buyout ImmunityBio purchases remaining minority shares Could be at a premium, fair value, or low valuation Remain a Controlled Subsidiary (Status Quo) GBIM stays under ImmunityBio control Share value remains speculative/illiquid Asset Transfer / Internal Restructuring Patents/IP moved within corporate structure Limited or no direct benefit to minority shareholders Reverse Merger or Strategic Transaction GBIM used as a vehicle for another asset or deal highly speculative Dissolution / Wind-Down If dissolved, shareholders are last in priority Unexpected Value Unlock IP monetization or strategic shift increases value No current public indication of this
1 · Reply
m1965
m1965 Feb. 13 at 6:13 PM
$GBIM That sucks !! Someone sold 190 shares and dropped the price to .000099
0 · Reply
m1965
m1965 Feb. 12 at 2:58 PM
$GBIM Someone sold 3k shares this morning. One day maybe we’ll all be selling at more than $.0001
1 · Reply
dee64
dee64 Feb. 10 at 5:25 AM
$GBIM Wish I could sell $GBIM as a tax write-off.
2 · Reply
Biofrog
Biofrog Feb. 2 at 1:27 AM
$IBRX $GBIM Sorry but not correct. The 2024 annual report says that IBRX discontinued research on the Tarmogen platform due to poor trial outcomes. But GBIM's other platform is Neoepitopes. Protein constructs created using yeast which IBRX is working on. The hope is that they could be part of/ inside of the hAd5 adenoviris for Covid, Lynch, but we don't know. If they are not than IBRX will maybe cancel GBIM but they have been maintaining a large plant in Colorado for 4 years where GBIM is at.
4 · Reply
Groov
Groov Feb. 2 at 1:08 AM
$GBIM $IBRX still holding 5000 GBIM Shares @ $2.53
1 · Reply
oceanviewhi
oceanviewhi Feb. 2 at 1:02 AM
$IBRX the relationship between GlobeImmune ($GBIM) and ImmunityBio ($IBRX) ImmunityBio (via NantCell) is the majority shareholder of GlobeImmune. Dr. Pat acquired a massive stake in 2017 to secure the Tarmogen® platform, which uses heat-inactivated yeast (S. cerevisiae) to stimulate T-cell immunity. The Tarmogen technology is now a key pillar of the "BioShield" vaccine strategy. Unlike traditional vaccines that rely on antibodies, Tarmogens activate cellular immunity, which is essential for killing tumors and clearing chronic viral infections like HIV. This is the "crown jewel" of the GlobeImmune portfolio. It targets the KRAS mutation, which is present in 90% of pancreatic cancers and 30-50% of colorectal and lung cancers. In 2026, this is being integrated into "basket trials" alongside Anktiva to see if Anktiva can amplify the T-cell response generated by GI-4000.
0 · Reply
Biofrog
Biofrog Jan. 31 at 9:48 PM
$GBIM $IBRX Hello my fellow GBIM'ers. Someone on IBRX is questioning our relationship with IBRX. Go to westjitter at 3:30 if you want for fun and my replies.
0 · Reply
m1965
m1965 Jan. 31 at 7:41 PM
$GBIM $IBRX
1 · Reply
Biofrog
Biofrog Jan. 30 at 9:26 PM
$GBIM $IBRX There is a royalty agreement that is pretty strong for us. If some of our yeast protein constructs wind up in a vaccine we will get something. I did math 3 years ago. I don't know where my notes are but I figured in a buy out for every 100mill in valuation our pps will be 17.4. And then we own 163,800 shares of IBRX.
8 · Reply
IBRXrallypossum002100
IBRXrallypossum002100 Jan. 30 at 4:25 PM
$GBIM Hey guys...so I guess this new rule squashed normal trading here...anyone know an alternate path to buy? https://blog.otcmarkets.com/2021/03/25/understanding-the-expert-market/
0 · Reply
IBRXrallypossum002100
IBRXrallypossum002100 Jan. 30 at 2:56 PM
$GBIM Hey guys.....Thinking about buying some here. My understanding is this entity owns IBRX shares, as a wholly owned subsidiary. Liquidity issues basically mean it's impossible to know when you can get out. Is there anyone selling here? L2 anyone?
1 · Reply
Biofrog
Biofrog Jan. 29 at 8:33 PM
$GBIM $IBRX I just mailed IBRX asking them if any of the GBIM yeast constructs are in the hAd5 adenovirus. Long shot they will answer.
1 · Reply
biotechmonkey
biotechmonkey Jan. 28 at 12:51 AM
$GBIM give us $2.X and I'll be good at this point.
3 · Reply
Runmaster83
Runmaster83 Jan. 27 at 1:40 AM
$GBIM Fo our shares still matter? IBRX is rolling, surely we will be compensated for our commitment?!
0 · Reply
dannymac65
dannymac65 Jan. 19 at 8:12 PM
$GBIM The only stock I have ever owned based on blind faith! I am assuming some light will shine on this one when IBRX achieves profitability which should be Soon. Good luck to us worms. We have been fed crap and kept in the dark for years! In the spirit of MLK, we are about to see the promised land imo.
0 · Reply
Joy0001
Joy0001 Jan. 18 at 4:08 PM
$GBIM Still hanging around all these years later hoping GBIM is invited to the IBRX party! Nice to see a few other faithfuls still in the mix!!
0 · Reply
dee64
dee64 Jan. 18 at 3:53 PM
$IBRX What about $GBIM shares that PSS reports under $IBRX finances?
0 · Reply
Teddy313
Teddy313 Jan. 16 at 3:51 PM
$GBIM Any idea what will happen with GBIM now that IBRX is going crazy to the upside. Maybe the good Dr. will do something with it. I'm still loaded, no cost sold a lot at 5.25 years ago. Now making money with IBRX...Just have a feeling something is going to happen. IMO....
2 · Reply
dee64
dee64 Jan. 5 at 10:31 AM
$GBIM Happy New Year!!!!! New beginnings for 2026.
0 · Reply